FDA AdComm Schedule Boosts BioMarin, Sinks Sarepta
This article was originally published in Scrip
Executive Summary
BioMarin Pharmaceutical Inc.'s investors pushed shares of the firm up 6% in morning trading on Oct. 14 after a notice was published early in the Federal Register – the place where the US government informs the public of federal actions, including plans for public meetings – confirming the FDA's Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) is set to examine the company's new drug application (NDA) for its Duchenne muscular dystrophy medicine drisapersen Nov. 24.